Previous close | 76.80 |
Open | 76.80 |
Bid | 70.15 |
Ask | 73.10 |
Strike | 85.00 |
Expiry date | 2024-06-21 |
Day's range | 76.80 - 76.80 |
Contract range | N/A |
Volume | |
Open interest | 25 |
Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment. Proteologix’s portfolio includes: PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma. PX130, a bispecific antibody t
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Johnson & Johnson said on Thursday it would acquire Proteologix for $850 million in cash, as it looks to gain access to the privately held company's experimental atopic dermatitis treatments. Proteologix's antibody PX128 is ready to enter early-stage development for moderate to severe atopic dermatitis, commonly referred to as eczema, and moderate to severe asthma. PX130, its other antibody, is in preclinical development for moderate to severe atopic dermatitis.